Gene targeting effects by topo i somerase inhibitors using plasma free DNA in patients with SCLC

拓扑异构酶抑制剂利用血浆游离 DNA 对 SCLC 患者进行基因靶向作用

• 批准号: 21790780
• 负责人: KIMURA Tatsuo
• 金额: $ 2.5万
• 依托单位: Osaka City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21790780/
• 关键词: 小細胞肺癌; トポイソメラーゼ阻害剤; 血漿DNA; イリノテカン; エトポシド; ァムルビシン; 肺癌; 呼吸器病学; トポイソメラーゼ

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy- sensitive and -refractory relapsed SCLC. I reviewed the applicability of AMR therapy for patients with SCLC on Clinical Medicine Insights Oncology 2011. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.

肺癌是癌症死亡的主要原因，大约15％的肺癌患者患有小细胞肺癌（SCLC）。尽管二线化疗可以产生肿瘤的消退，但预后却很差。 Amrubicin盐酸（AMR）是一种合成的蒽环类抗癌剂和有效的拓扑异构酶II抑制剂。 AMR具有可预测且可管理的毒性，是治疗化学疗法敏感和 - fractractory复发SCLC的最有吸引力的药物之一。我回顾了AMR治疗对SCLC患者在临床医学见解肿瘤学2011年的适用性。这些临床试验（包括III期研究）将阐明AMR在SCLC治疗中的状态。

项目成果

Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.

使用氨柔比星治疗 3 天的患者中，氨柔比星的平台期血浆浓度与血液学毒性相关。

• 发表时间: 2009
• 期刊: Anticancer Drugs (掲載確定)
• 作者: Kimura T;et al.
• 通讯作者: et al.

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.

多西紫杉醇和卡铂治疗老年晚期非小细胞肺癌的 II 期研究。

• 发表时间: 2009
• 期刊: J Thorac Oncol. 4
• 作者: Yoshimura N;Kudoh S;Kimura T;Mitsuoka S;Kyoh S;Tochino Y;Asai K;Kodama T;Ichimaru Y;Yana T;Hirata K
• 通讯作者: Hirata K

Soft Tissue Squamous Cell Carcinoma in Chest Wall with an Incomplete Border Sign

胸壁软组织鳞状细胞癌，边界不完整

• 发表时间: 2011
• 期刊: J Med Cases 2(1)
• 作者: Kimura T;Kudoh S;Tochino Y;Kodama T;Matsumura S;Hirata K
• 通讯作者: Hirata K

Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC.

日本 NSCLC 患者中厄洛替尼与吉非替尼不良事件的比较。

• 发表时间: 2010
• 作者: Suzumura T;Kudoh S;Kimura T;Umakawa K;Tanaka H;Mitsuoka S;Yoshimura N;Hirata K.
• 通讯作者: Hirata K.

Feasibility study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer.

日本完全切除 II-IIIA 期非小细胞肺癌患者辅助长春瑞滨和顺铂的可行性研究。

• 发表时间: 2010
• 作者: Yoshimura N;Kudoh S;Mitsuoka S;Kimura T;Hirata K.
• 通讯作者: Hirata K.